NCT ID	NCT05382442
Title	A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2022-05-19
Location	California, United States China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	5-Fluorouracil, Bevacizumab, capecitabine, Irinotecan, Leucovorin, oxaliplatin
Tags	MSS/ MMRp
NCT ID	
Title	NCT05382741 Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
Phase	Phase 2
Date Added	2022-05-19
Location	Italy
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Durvalumab Injection for intravenous use 500 mg vial solution for infusion, Regorafenib 30 mg capsules, Imfinzi, Stivarga
Tags	MSS/ MMRp
	NCT05350917
Title	Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
Phase	Phase 2
Date Added	2022-04-28
Location	
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Not yet recruiting
Drugs	Tislelizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
	NCT05349890
Title	Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Phase	Phase 1
Date Added	2022-04-27
Location	Oregon, United States
Prior IO Allowed	Yes
CRC-directed	Νο
Status	Active, not recruiting
Drugs	CDX-1140, Pembrolizumab, Keytruda
Tags	MSI-H/ MMRd, MSS/ MMRp
	NCT05333809
Title	Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2022-04-19

Location	
Prior IO Allowed	No
CRC-directed	Yes
Status	Not yet recruiting
Drugs	Disitamab vedotin, Pembrolizumab, Keytruda
Tags	MSS/ MMRp
	NCT05328908
Title	A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines
	of Metastatic Colorectal Cancer
Phase	Phase 3
Date Added	2022-04-14
Location	Arkansas, United States California, United States Florida, United States Idaho, United States Idaho, United States Idaho, United States Idaho, United States Massachusetts, United States Michigan, United States North Carolina, United States North Carolina, United States North Carolina, United States Ohio, United States South Carolina, United States Virginia, United States Canada Chila Carolia Germany It
	Taiwan
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga
Tags	MSS/ MMRp
NCT ID	NCT05319314
Title	GCC19CART for Patients With Metastatic Colorectal Cancer
Phase	Phase 1

Location California, United States Coiceado, United States Michigar, United States Prior IO Allowed Vis CRC-directed Yes Status Recruiting Drugs GCC190CART Tags MSH-M MiRel, MSS/ MMRp NTID NC10530846 Title That Have a BRAF Mutation Date Added 222 04-04 Location Alizona, United States California, United States California, United States Cationia Alizona, United States Cationia California, United States Cationia United States Indiana, United States California, United States Indiana, United States Minescali, United States Minescali, Uni		
Colorada, Unities States Michigan, Unities States Torse, Unities States Prior ID Allowed Yes CRC-directd Yes Status Reculating Drugs GCC 10CART Tage MSI-W MMR4, MSS/ MMRp NCT D NCT05308446 Title Testing the Addition of Nicolumab to Standard Treatment for Patients With Metastatic or Unresectable Colored That Have a BRAF Mutation Phase 2 Date Addition of Nicolumab to Standard Treatment for Patients With Metastatic or Unresectable Colored That Have a BRAF Mutation Phase 2 California, United States California, United States California, United States California, United States California, United States Indira, United States California, United States Indira, United States Nontrana, United States Indira, United States Northana, United States Northana, United States Northana, United States Nort		2022-04-08
Massachusets, United States Toras, United States Prior ID Allowed Ve CRC-directed Ve Status Recruiting Drugs CC1 (SCART Tage MSI-W MMRd, MSS/ MMRp CRT ID NCT SDS3084/6 Toras, United States Testing the Addition of Nicolumab to Standard Treatment for Patients With Metastatic or Unresoctable Colorer That Hove a BARF Mutation Phase Date Added Date Added Colored, United States Colored, United States Colored, United States Colored, United States Colored, United States Colored, United States Nonau, United States Unois, United States Nonau, United States Unois, United States Nonau, United States Unois, United States Nonau, United States Nonau, United States Nonau, United States <t< td=""><td>cation</td><td></td></t<>	cation	
Texas. United States Prior ID Allowed Yes CRC - directed Yes Status Recruiting Drugs GCC18-CART Tags MSI-H/ MRAU, MSS/ MRXp NT ID NCT053084-6 Title Testing the Addition of Nicolumab to Standard Treatment for Patients With Metastatic or Unresectable Colored That Have a BRAF Mutation Phase Phase 2 Dete Added 22/20-40-40 Location California, United States Carrent United States California, United States Goorgia, United States California, United States Hodana, United States Minescott, United States Hodana, United States Minescott, United States Morran, United States Minescott, United States Morran, United States Minescott, United States North Carrella, United States Minescott, United States Morran, United States Minescott, United States Morran United States Minescott, United States Morran United States Minescott, United States Morran United States Minescott, United States		
Prior 10 Allowed Ves CRC-directed Ves Status Recruiting Drugs GCC19CART Tags MSI-H/ MMRd, MSS/ MMRp NCT D NCT05000440 Title Testing the Addition of Nicolumab to Standard Treatment for Patients With Metastatic or Unresectable Coloreer Trans there as BAFF Mutation Phase Phase 2 Data Added 2022-04-04 Location Atzona, United States Colorado, United States Colorado, United States Colorado, United States Colorado, United States Colorado, United States Locationa, United States Ininos, United States Ininos, United States Ininos, United States Ininos, United States Ininos, United States Ininos, United States New Hempeline, United States Ininos, United States New Hempeline, United States		
CRC-sinected Yes Status Rocruling Drugs GCC192ART Tags MSH-MMR2.MSS/MMRp NCT D NCT0530844. Title Testing the Addition of Nicolumab to Standard Treatment for Patients With Metastatic or Unresectable Colored That Have a BRAF Mutation Phase Plase 2 Date Added Addition of Nicolumab to Standard Treatment for Patients With Metastatic or Unresectable Colored That Have a BRAF Mutation Phase Q222-04-04 Location Atizona, United States Calorina, United States Calorina, United States Calorina, United States Indiana, United Sta		Texas, United States
Status Recruining Drugs GCC19CART Tags MSI-H/ MMRd, MSS/ MMRp NCT ID NCT05008446 Title Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorec Trained Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorec Calorina, United States Place Phase 2 Date Added 222-04-04 Coardou, United States Calorina, United States Calorina, United States Calorina, United States Coardou, United States Calorina, United States Illinois, United States Illinois, United States Illinois, United States Illinois, United States Investor, United States Illinois, United States Investor, United States Illinois, United States Missouri, United States Illinois, United States Missouri, United States Illinois, United States Normarta, United States Illines North Carolina, United S	ior IO Allowed	Yes
progs GCC 19CART Tags MSI-MV MMRd, MSS/ MMRp NCT ID NCT05308446 Title Tasking the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresoctable Colored That Have a BAF Mutation Phase Phase 2 Dete Added 2022-04-04 Location Arizona, United States Calorato, United States Calorato, United States Calorato, United States Calorato, United States Illinois, United States Illinois, United States Illinois, United States Illinois, United States Illinois, United States Networks, United States Illinois, United States Michigan, United States	<pre>C-directed</pre>	Yes
Tags MSI-H/ MMRd, MSS/ MMRp NCT ID NCT05308446 Title Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresoctable Colored That Have a BRAF Mutation Phase Phase 2 Date Added 2022-04-04 Location Atizona, United States California, United States California, United States Georgia, United States Ibrain, United States Ibrain, United States Ibrains, United States Ibrains, United States New Jampahine, United States New Jampahine, United States New Jampahine, United States New Jampahine, United States New Varsey, United States New Jampahine, United States New Varsey, United States New Varsey, United States New Varsey, United States Neo Istates	atus	Recruiting
NCT ID NCT D3398446 Title Testing the Addition of Nvolumab to Standard Treatment for Patients With Metastatic or Unresectable Colored That Have a BRAF Mutation Phase Phase 2 Date Added 2022-04-04 Location California, United States Colorado, United States Colorado, United States Colorado, United States California, United States Colorado, United States Colorado, United States Illinois, United States Illinois, United States Illinois, United States Markingan, United States Illinois, United States Markingan, United States Montana, United States Montana, United States Montana, United States Montana, United States Montana, United States Montana, United States North Carolina, United States North Carolina, United States New Jersey, United States Okahoma, United States New Jersey, United States Okahoma, United States New Jersey, United States Oregon, United States North Carolina, United States Oregon, United States Oregon, United States Oregon, United States North Carolina, United States Tennessee, United States <t< td=""><td>ugs</td><td>GCC19CART</td></t<>	ugs	GCC19CART
Title Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colored That Have a BRAF Mutation Phase Phase 2 Date Added 2022-04-04 Location Arizona, United States California, United States Colored, United States Colored, United States Colored, United States Colored, United States Indiana, United States Indiana, United States Indiana, United States Indiana, United States Indiana, United States Indiana, United States Indiana, United States Indiana, United States Indiana, United States Indiana, United States Michigan, United States Michigan, United States Indiana, United States Michigan, United States Michigan, United States New York, United States New York, United States Michigan, United States New York, United States New York, United States Michigan, United States Origon, United States Origon Michigan, United States Michigan, United States New York, United States New York, United States Michigan, United States Michigan, United States Origon, United States Conton Colores	gs	MSI-H/ MMRd, MSS/ MMRp
That Have a BRAF Mutation Phase Phase 2 Date Added 2022-04-04 Location Arizona, United States California, United States California, United States California, United States California, United States Georgia, United States California, United States Idano, United States California, United States Idano, United States California, United States Indian, United States California, United States Minnesora, United States Minnesora, United States Montana, United States North, Canolina, United States New Versey, United States North, Canolina, United States New Versey, United States New Versey, United States New Versey, United States New Versey, United States Versey, United States South Carolina, United States Versey, United States New Versey, United States Versey, United States New Versey, United States Versey, United States New Versey,	T ID	NCT05308446
Date Added2022-04-04LocationArizona, United States California, United States Colorado, United States Georgia, United States Idaho, United States Idaho, United States Indiana, United States Indiana, United States Indiana, United States Indiana, United States Massing, United States New Hampshire, United States New Hampshire, United States New Hampshire, United States New Jessey, United States New Jessey, United States New Jessey, United States Origin, United States Texas, United	le	Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
Location Arizona, United States California, United States California, United States Georgia, United States Georgia, United States Hawaii, United States Hawaii, United States Indina, United States Indina, United States Indina, United States Indina, United States Indina, United States Indina, United States Michigan, United States Michigan, United States Michigan, United States Michies, United States Minscout, United States Montana, United States Minscout, United States New York, United States New York, United States North Carolina, United States New Jersey, United States North Carolina, United States Oragon, United States Oragon, United States New Jersey, United States South Carolina, United States Oragon, United States South Carolina, United States South Carolina, United States South Carolina, United States Versonst, United States Westington, Unit	lase	Phase 2
California, United States Colorado, United States Georgia, United States Hawaii, United States Idaho, United States Idana, United States Indiana, United States Louisiana, United States Louisiana, United States Louisiana, United States Louisiana, United States New Hampshire, United States Nontrad, United States New York, United States Nont Carolina, United States New York, United States Noth Carolina, United States New York, Unite	ite Added	2022-04-04
Colorado, United StatesHavaii, United StatesHavaii, United StatesIllinois, United StatesMichigan, United StatesMinescuta, United StatesMinescuta, United StatesMinescuta, United StatesMontana, United StatesMontana, United StatesNew Jersey, United StatesNew Versey, United StatesOhio, United StatesNew Versey, United StatesOhio, United StatesOhio, United StatesOhio, United StatesOhio, United StatesOhio, United StatesOhio, United StatesPennsylvania, United StatesRhode Island, United StatesRhode Island, United StatesTennessee, United StatesTennessee, United StatesTennessee, United StatesVest Virginia, United States	cation	Arizona, United States
Georgia, United States Hawaii, United States Hawaii, United States Ilinois, United States Ilinois, United States Iowa, United States Lousiana, United States Lousiana, United States Moletiga, United States Moletiga, United States Monta, United States New Hampshire, United States New Jersey, United States Origon, United States New Jersey, United States New Jersey, United States Noho, United States Noho Isales Pennsylvani, United States Noho Isales Tennessee, United States Noho Isales Tennessee, United States Yermont, Yermont, Yermont, Yermont, Yermo		
Hawaii, United States Idaho, United States Illinois, United States Illinois, United States Iowa, United States Iowa, United States Iowa, United States Iowa, United States Iowa, United States Minesota, United States Minesota, United States Minesota, United States Minesota, United States New Hampshire, United States New York, United States Ohio, United States Ohio, United States Ohio, United States New York, United States Yermont, United St		
Illinois, United StatesIowa, United StatesIowa, United StatesIowa, United StatesMinesota, United StatesMinesota, United StatesMinesota, United StatesMonana, United StatesMonana, United StatesMonana, United StatesNew Hampshire, United StatesNew Jersey, United StatesNew York, United StatesNew York, United StatesNew York, United StatesOklahoma, United StatesSouth Carolina, United StatesSouth Carolina, United StatesSouth Carolina, United StatesSouth Carolina, United StatesVermont, United StatesNet StatesNet StatesNet StatesNet States<		-
Indiana, United StatesLousiana, United StatesLousiana, United StatesMichigan, United StatesMichigan, United StatesMiscouri, United StatesMontana, United StatesMontana, United StatesNew Hampshire, United StatesNew Hampshire, United StatesNew Hampshire, United StatesNew York, United StatesNew York, United StatesNew York, United StatesNew York, United StatesOhio, United StatesOhio, United StatesOkiahoma, United StatesOkiahoma, United StatesNuted StatesNuted StatesNuted StatesOkiahoma, United StatesNuted StatesVergen, United StatesVergen, United StatesVergen, United StatesTenesese, United StatesTenesese, United StatesTenesese, United StatesVergen, United StatesNet OK2PolytiekMisouriekMisouriekNet OK2Vergen, United StatesNet OK2Vergen, United States </td <td></td> <td>Idaho, United States</td>		Idaho, United States
Iowa, United StatesLouisiana, United StatesMichigan, United StatesMissouri, United StatesMissouri, United StatesMontana, United StatesMontana, United StatesNew Hampshire, United StatesNew Jersey, United StatesNew York, United StatesNew York, United StatesOhio, United StatesOhio, United StatesOhio, United StatesOregon, United StatesPennsylvania, United StatesRobole Island, United StatesTeanessee, United StatesVermont, United StatesVermont, United StatesVermont, United StatesVermont, United StatesVerwont, United Stat		
Louisiana, United StatesMichigan, United StatesMinsouri, United StatesMissouri, United StatesNew Hampshire, United StatesNew Jarsey, United StatesNew Jarsey, United StatesNorth Carolina, United StatesOhio, United StatesOhio, United StatesNorth Carolina, United StatesOhio, United StatesOhio, United StatesOhio, United StatesOhio, United StatesOhio, United StatesOhio, United StatesOregon, United StatesTorvas, United StatesTorvas, United StatesTorvas, United StatesVermont, United StatesVermont, United StatesVermont, United StatesVermont, United StatesVermont, United StatesVermont, United StatesVerto RicoPrior IO AllowedCRC-directedMS/ MRPNCT IDNCT IDNCT IDNCT USNCT IDInpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastate I		
Minnesota, United StatesMissouri, United StatesMontana, United StatesNew Hampshire, United StatesNew Jorsey, United StatesNew York, United StatesOhio, United StatesOhio, United StatesOhio, United StatesOklahoma, United StatesPennsylvania, United StatesSouth Carolina, United StatesSouth Carolina, United StatesTenessee, United StatesTenessee, United StatesVermort, United StatesVest Virginia, United StatesVest Virginia, United StatesVest Virginia, United StatesVest Virginia, United StatesVest Nicoonsin, United StatesNotoscopeRotie, NotoscopeRotie, Notoscope		
Missouri, United States Montana, United States New Hampshire, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Ohio, United States Oklahoma, United States Oklahoma, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Pennsylvania, United States Ternessee, United States Ternessee, United States Ternessee, United States Versont, United States Versont, United States Versont, United States Ternessee, United States Ternessee, United States Ternessee, United States Versont, United States Ternessee, United States Versont, United States Ternessee, United States Versont, Uni		Michigan, United States
Montana, United StatesNew Hampshire, United StatesNew Jensey, United StatesNew York, United StatesNorth Carolina, United StatesOhio, United StatesOhio, United StatesOregon, United StatesOregon, United StatesOregon, United StatesPennsylvania, United StatesSouth Carolina, United StatesSouth Carolina, United StatesPennsylvania, United StatesSouth Carolina, United StatesVermont, United StatesVertor OtallowedNoCRC-directedProgStatusActive, not recruitingDrugscetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, OpdivoTagsNCT IDNCT DDTitleImpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastate U		
New Hampshire, United StatesNew York, United StatesNew York, United StatesNew York, United StatesOhio, United StatesOhio, United StatesOklahoma, United StatesOklahoma, United StatesOregon, United StatesOregon, United StatesOregon, United StatesOregon, United StatesPennsylvania, United StatesSouth Carolina, United StatesSouth Carolina, United StatesTernessee, United StatesTernessee, United StatesTernessee, United StatesVermont, United StatesVerto RicoProt IO AllowedNoCRC-directedYesStatusActive, not recruitingDrugscetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, OpdivoTagsNCT IDNCT05299840TitleImpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastated United States		
New Jersey, United StatesNew York, United StatesNorth Carolina, United StatesOklahoma, United StatesOklahoma, United StatesOregon, United StatesOklahoma, United StatesOklahoma, United StatesPennsylvania, United StatesSouth Carolina, United StatesFonessee, United StatesSouth Carolina, United StatesVermont, United StatesTennessee, United StatesTennessee, United StatesVermont, United StatesVerto RicoProto IO AllowedNoCRC-directedYesStatusActive, not recruitingDrugscetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, OpdivoTagsNCT IDNCT IDTitleInpact of Using the Oncogramme(R) Device to Select the First Line of Treatment fo		
North Carolina, United StatesOhio, United StatesOhio, United StatesOklahoma, United StatesOregon, United StatesOregon, United StatesPennsylvania, United StatesRhode Island, United StatesSouth Carolina, United StatesSouth Carolina, United StatesTernessee, United StatesTernessee, United StatesTexas, United StatesVermont, United StatesVermont, United StatesVermont, United StatesVermont, United StatesVermont, United StatesVermont, United StatesVersoni, United StatesVersonicoStatusActive, not recruitingDrugscetuximab, encoralenib, Nivolumab, Braftovi, Erbitux, OpdivoTagsNCT IDNCT05299840TitleImpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic of Using the Oncogramme (R) Device to Select the First Line of Treatment for Patients With Metastatic o		
Ohio, United States Oklahoma, United States Pennsylvania, United States Pennsylvania, United States South Carolina, United States South Carolina, United States Tennessee, United States Terxas, United States Tevmont, United States Utah, United States Washington, United States West Virginia, United States West Virginia, United States Perto RicoPrior IO AllowedNoCRC-directedYesStatusActive, not recruiting DrugsDrugscetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, OpdivoTagsMSS/MMRpNCT IDNcT05299840TitleImpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic of the States of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic of Using the Oncogramme (R) Device to Select the First Line of Treatment for Patients With Metastatic of Using the Oncogramme (R) Device to Select the First Line of Treatment for Patients With Metastatic of Using the Oncogramme (R) Device to Select the First Line of Treatment for Patients With Metastatic of Using the Oncogramme (R) Device to Select the First Line of Treatment for Patients With Metastatic of Using the Oncogramme (R) Device to		
Oklahoma, United StatesOregon, United StatesPennsylvania, United StatesRhode Island, United StatesSouth Carolina, United StatesSouth Carolina, United StatesUtah, United StatesUtah, United StatesVermont, United StatesUtah, United StatesVermont, United StatesVermont, United StatesVermont, United StatesVermont, United StatesVermont, United StatesVerst Virginia, United StatesVerst		
Pennsylvania, United StatesRhode Island, United StatesSouth Carolina, United StatesTennessee, United StatesTexas, United StatesVermont, United StatesVermont, United StatesVermont, United StatesVermont, United StatesVermont, United StatesVermont, United StatesVertor, United StatesVertor, United StatesVest Virginia, United S		
Rhode Island, United StatesSouth Carolina, United StatesTennessee, United StatesTexas, United StatesUtah, United StatesVermont, United StatesVermont, United StatesWest Virginia, United StatesWisconsin, United StatesPrior IO AllowedNoCRC-directedStatusActive, not recruitingDrugscetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, OpdivoTagsNCT IDNCT IDTiteImpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastated of the Select the First Line of Treatment for Patients With Metastated of the Select the First Line of Treatment for Patients With Metastated of the Select the First Line of Treatment for Patients With Metastated of the Select the First Line of Treatment for Patients With Metastated of the Select the First Line of Treatment for Patients With Metastated of the Select the First Line of Treatment for Patients With Metastated of the Select the First Line of Treatment for Patients With Metastated of the Select the First Line of Treatment for Patients With Metastated of the Select the First Line of Treatment for Patients With Metastated of the Select the First Line of Treatment for Patients With Metastated of the Select the First Line of Treatment for Patients With Metastated of the Select the First Line of Treatment for Patients With Metastated of the Select the First Line of Treatment for Patients With Metastated of the Select the First Line of Treatment for Patients With Metastated of the Select the First Line of Treatment for Patients With Metastated of the Select the First Line of Treatment for Patients With Metastated of the Select the First Line of Treatment for Patients With Metastat		Oregon, United States
South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States West Virginia, United States Puerto RicoPrior IO AllowedNoCRC-directedYesStatusActive, not recruiting cetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, OpdivoTagsMSS/ MMRpNCT IDNCT0529840TiteImpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic of the patient of th		
Tennessee, United States Texas, United States Utah, United States Vermont, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Puerto RicoPrior IO AllowedNoCRC-directedYesStatusActive, not recruiting terusmab, encorafenib, Nivolumab, Braftovi, Erbitux, OpdivoTagsMSS/MMRpNCT IDNCT05299840TitleImpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastated of the Section o		
Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Puerto RicoPrior IO AllowedNoCRC-directedYesStatusActive, not recruiting DrugsDrugscetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, OpdivoTagsNCT IDNCT IDNCT05299840TitleImpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastated of the Section of the		
Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Puerto RicoPrior IO AllowedNoCRC-directedYesStatusActive, not recruiting cetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, OpdivoTagsMSS/ MMRpNCT IDNCT05299840TitleImpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic		
Washington, United States West Virginia, United States Wisconsin, United States Puerto RicoPrior IO AllowedNoCRC-directedYesStatusActive, not recruitingDrugscetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, OpdivoTagsMSS/MMRpNCT IDNcT05299840TitleImpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastation		
West Virginia, United States Wisconsin, United States Puerto RicoPrior IO AllowedNoCRC-directedYesStatusActive, not recruiting cetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, OpdivoTagsMSS/MMRpNCT IDNcT05299840TitleImpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastation		
Wisconsin, United States Puerto RicoPrior IO AllowedNoCRC-directedYesStatusActive, not recruitingDrugscetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, OpdivoTagsMSS/MMRpNCT IDNCT05299840TitleImpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastation		
Prior IO AllowedNoCRC-directedYesStatusActive, not recruitingDrugscetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, OpdivoTagsMSS/MMRpNCT IDNCT05299840TitleImpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastation		
CRC-directedYesStatusActive, not recruitingDrugscetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, OpdivoTagsMSS/ MMRpNCT IDNCT05299840TitleImpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic of Contract of		Puerto Rico
Status Active, not recruiting Drugs cetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, Opdivo Tags MSS/ MMRp NCT ID NCT05299840 Title Impact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic of Comparison of Co	ior IO Allowed	No
Drugs cetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, Opdivo Tags MSS/ MMRp NCT ID NCT05299840 Title Impact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the	C-directed	Yes
Tags MSS/ MMRp NCT ID NCT05299840 Title Impact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients With Metastatic of the Select the First Line of Treatment for Patients Assect the Select the First Line of Treatment for Patients Assect	atus	Active, not recruiting
NCT ID NCT05299840 Title Impact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Comparison of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Comparison of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Comparison of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Comparison of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Comparison of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Comparison of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Comparison of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Comparison of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Comparison of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Comparison of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Comparison of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Comparison of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Comparison of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Comparison of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Comparison of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Comparison of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patient for Patients With Metastatic Comparison of	ugs	cetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, Opdivo
Title Impact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic	gs	MSS/ MMRp
		NCT05299840
	le	Impact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Cancer
Phase Not Applicable	lase	Not Applicable
Date Added 2022-03-29		

Location	France
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05292417
Title	Radiotherapy in Combination With Sintilimab?GM-CSF and Fruquintinib in Patients With MSS mCRC
Phase	Phase 2
Date Added	2022-03-23
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Fruquintinib, GM-CSF, Sintilimab
Tags	MSS/ MMRp